
|Videos|December 2, 2022
Dr. Laura Sena discusses bipolar androgen therapy for prostate cancer
Author(s)Urology Times staff
“This is different from other standard-of-care therapies for prostate cancer because usually we are inhibiting androgen receptor (AR) activity and here we’re actually stimulating AR,” explained Laura Anne Sena, MD, PhD.
Advertisement
Video Player is loading.
In an interview during the
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Community practice experience shows early efficacy, favorable safety with nadofaragene
2
Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer
3
ORIC-944 shows promise in combination with ARPIs for mCRPC
4
Suzanne Merrill, MD, on integrating ICIs into clinical practice for NMIBC
5




















